A comprehensive analysis of CD38 expression on various immune cells in patients with autoimmune diseases could facilitate the dosing possibility of depleting only plasmablasts and plasma cells without affecting other potentially beneficial cells. This evidence concerns the gene CD38 and autoimmune disease.